Content by Keyword: Drugs, Medical Devices, and Pharmacy Services

  • Home
  • Drugs, Medical Devices, and Ph...
Report page
Estimate of Cocaine Users in the U.S.

Market Barriers to the Development of Pharmacotherapies for the Treatment of Cocaine Abuse and Addiction: Final Report. Estimate of Cocaine Users in the U.S.

There are more than 2 million addicted or "heavy" cocaine users. Of these, as many as 800,000 to 900,000 may enter treatment at least once in a given year. On any given day, roughly 250,000 cocaine abusers are enrolled in treatment (i.e., who are at a residential facility or have been served at an ambulatory treatment center within the previous 30
Report page
Principal Findings

Market Barriers to the Development of Pharmacotherapies for the Treatment of Cocaine Abuse and Addiction: Final Report. Principal Findings

Report page
Methods

Market Barriers to the Development of Pharmacotherapies for the Treatment of Cocaine Abuse and Addiction: Final Report. Methods

This study relied on several types of sources for information about cocaine pharmacotherapies and the market barriers to their development. These included:
Report page
Principal Conclusions

Market Barriers to the Development of Pharmacotherapies for the Treatment of Cocaine Abuse and Addiction: Final Report. Principal Conclusions

Under current conditions, pursuing development of a new cocaine pharmacotherapy via a typical full product development cycle is not economically viable from the standpoint of industry. Although a variety of hurdles or procedural impediments may affect prospects for new pharmacotherapy development in this area, most of these are regarded as surmoun
Report page
Purpose

Market Barriers to the Development of Pharmacotherapies for the Treatment of Cocaine Abuse and Addiction: Final Report. Purpose

The purpose of this project was to produce an analysis of the market barriers to the development of pharmacotherapies for substance abuse and addiction, and for cocaine abuse and addiction in particular. The analysis is intended to provide ASPE with information related to four areas:
Report page
Executive Summary

Market Barriers to the Development of Pharmacotherapies for the Treatment of Cocaine Abuse and Addiction: Final Report. Executive Summary

PDF report
State Government Employer-Sponsored Prescription

State Government Employer-Sponsored Prescription Drug Coverage Strategies to Optimize Cost Control and Use of Prescription Drugs

Updated Analyses of Trends in Use of Assistive

Updated Analyses of Trends in Use of Assistive Devices

Updated Analyses of Trends in Use of Assistive Devices Executive Summary Brenda Spillman Urban Institute January 7, 2013 REVISED January 20, 2014
Accelerating Adoption of Assistive Technology to

Accelerating Adoption of Assistive Technology to Reduce Physical Strain among Family Caregivers of the Chronically Disabled Elderly Living at Home

Analysis of Supply, Distribution, Demand, and

Analysis of Supply, Distribution, Demand, and Access Issues Associated with Immune Globulin Intravenous (IGIV)

Contents IGIV Supply and Distribution - Key Findings IGIV Demand - Key Fundings IGIV Access Problems- Key Fundings
Issues in the Design and Implementation of Drug

Issues in the Design and Implementation of Drug Formularies and Therapeutic Classes

As part of the Medicare Part D pharmacy benefit scheduled for implementation in 2006 by the Medicare Prescription Drug, Improvement, and Modernization Act (MMA), beneficiaries will have a choice of private plans administering the benefit.? Although plans are required to provide access to needed drugs, the law does not require plans to provide equa
Options for Defining Medicare Advantage Regions:

Options for Defining Medicare Advantage Regions: An Assessment of Tradeoffs

Contents  
Health Care in Transition:

Health Care in Transition: Technology Assessment in the Private Sector

Health Care in Transition: Technology Assessment in the Private Sector Prepared by: Richard Rettig of the RAND Corporation Office of the Assistant Secretary of Planning and Evaluation Agency for Health Care Policy and Research. July, 1996.
Prescription Drug Coverage, Spending, Utilization

Prescription Drug Coverage, Spending, Utilization, and Prices

Prescription drugs play an ever-increasing role in modern medicine. New medications are improving health outcomes and quality of life, replacing surgery and other invasive treatments, and quickening recovery for patients who receive these treatments. As important as prescription drugs are, not everyone has access to them. The newest drugs are ofte
PDF report
Updated Analyses of Trends in Use of Assistive

Updated Analyses of Trends in Use of Assistive Devices

Over the 20 year period 1984-2004, use of assistive devices by older Americans (age 65 and older) residing in the community increased greatly. In 1984, 72% of chronically disabled older Americans made some use of assistive devices, with or without additional human help to perform activities of daily living (i.e., tasks such as bathing, dressing
  • astdevup.pdf
    export-csvPDF
PDF report
Accelerating Adoption of Assistive Technology to

Accelerating Adoption of Assistive Technology to Reduce Physical Strain among Family Caregivers of the Chronically Disabled Elderly Living at Home

This report examines and assesses the often overlooked potential of assistive technology (AT) to benefit unpaid family caregivers who assist chronically disabled elders living at home. Although research has identified benefits, only a handful of publicly-funded family caregiver support programs give much attention to enabling caregivers’ access
  • AccAdoAT.pdf
    export-csvPDF
PDF report
Expanding the Use of Generic Drugs

Expanding the Use of Generic Drugs

Dramatic growth in the use of generic drugs has generated substantial savings for American consumers. To examine how the Department of Health and Human Services (HHS) can encourage the use of generic drugs, the Assistant Secretary for Planning and Evaluation (ASPE) examined barriers to, and opportunities for, expanding the use of generic drugs.
From: Expanding the Use of Generic Drugs
PDF report
Medicaid Contracts with Medicare Special Needs

Medicaid Contracts with Medicare Special Needs Plans Reflect Diverse State Approaches to Dually Eligible Beneficiaries

This paper is the third in a series on SNPs and their relationship to Medicaid. In the second paper of the series, we identified all states which had some kind of contractual relationship with SNPs prior to MIPPA, and classified those relationships into broad categories. The purpose of this third paper is to examine in greater detail a select grou
From: Medicaid Contracts with Medicare Special Needs Plans Reflect Diverse State Approaches to Dually Eligible Beneficiaries
  • SNPdual.pdf
    export-csvPDF
PDF report
Economic Analysis of Availability of Follow-on

Economic Analysis of Availability of Follow-on Protein Products

Unlike most conventional drugs, biological products are usually large, complex molecules that are produced by living organisms. These commercially engineered biologics currently account for billions of dollars in health care spending. Starting early last century, Congress has regulated most biologics separately from small molecules under the Bio
  • report.pdf
    export-csvPDF
PDF report
Federal Authority for Medicare Special Needs

Federal Authority for Medicare Special Needs Plans and their Relationship to State Medicaid Programs

This Brief reviews the history and current status of federal special needs plans (SNPs) authority, with particular attention to provisions of interest to state Medicaid programs that have or are considering entering into contracts with SNPs to integrate or coordinate Medicaid long-term care services with Medicare primary, acute and prescription dr
From: Federal Authority for Medicare Special Needs Plans and their Relationship to State Medicaid Programs
  • leghist.pdf
    export-csvPDF

Pages